FTM
BECOME A MEMBER
() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: Organic Cannabis

  • Home
  •  | 
  • Tag Archives: "Organic Cannabis"

Organigram signs supply agreement with Newfoundland and Labrador Liquor Corporation

Organigram signs supply agreement with Newfoundland and Labrador Liquor Corporation
Organigram signs supply agreement with Newfoundland and Labrador Liquor Corporation MONCTON, NB, Sept. 14, 2018 CNW/ - Organigram Holdings Inc. (TSX VENTURE: OGI) (OTCQX: OGRMF), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of medical marijuana, is pleased to announce that the Company has signed a supply agreement with the Newfoundland and Labrador…
Read more

Organigram Update on Proposed Investment in European CBD Hemp Producer Eviana

Organigram Update on Proposed Investment in European CBD Hemp Producer Eviana
Sept. 14, 2018 /CNW/ - Organigram Holdings Inc. (TSX VENTURE: OGI) (OTCQX: OGRMF), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of medical marijuana, is pleased to update the market on its proposed investment in Eviana Health Corporation ("Eviana"). The information provided in this news release is meant to update and replace the information previously disseminated by Organigram on June 4, 2018 regarding a proposed investment in Eviana.
Read more

Organigram invests in Hyasynth Biologicals Inc., helps bring transformative “cellular agriculture” to Canadian cannabis industry

Organigram invests in Hyasynth Biologicals Inc., helps bring transformative “cellular agriculture” to Canadian cannabis industry
Sept. 13, 2018 /CNW/ - Organigram Holdings Inc. (TSX VENTURE: OGI) (OTCQX: OGRMF), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of medical marijuana, is pleased to announce the closing of its strategic investment in convertible secured debentures (the "Debentures"), to be purchased in three tranches and valued in the aggregate at $10 million, of Hyasynth Biologicals Inc. ("Hyasynth"), a biotechnology company based in Montreal and leader in the field of cannabinoid science and biosynthesis.
Read more